5 items found

Tags: Belgian cost-utility analysis Background Biotechnology reimbursement

Filter Results
  • dataset

    IC, IE & ICERs for the base case scenario (GOG-0218 (st.IV), ICON7 (high risk...

    IC, IE & ICERs for the base case scenario (GOG-0218 (st.IV), ICON7 (high risk), OCEANS, and AURELIA).
  • dataset

    Mean treatment duration and bevacizumab treatment costs.

    Mean treatment duration and bevacizumab treatment costs.
  • dataset

    QoL values.

    QoL values.
  • dataset

    r37980778c78--9204f1ba0aeb1cfe5c742fda76a6327c

    Eligible patient population and bevacizumab treatment schedules in 4 peer-reviewed RCTs.
  • dataset

    First- and second-line bevacizumab in ovarian cancer: A Belgian cost-utility ...

    BackgroundCurrently, in Belgium, bevacizumab is reimbursed for ovarian cancer patients, based on a contract between the Minister and the manufacturer including confidential...